Document Detail


Felbamate as add-on therapy.
MedLine Citation:
PMID:  8738944     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Felbamate is a novel anti-epileptic drug (AED) which has recently been associated with reports of aplastic anaemia and liver failure. We have conducted an open-label add-on assessment of the tolerability and efficacy of this compound in 111 adult patients with refractory epilepsy attending a tertiary referral centre. The mean follow-up period was 4 months (range 1-8 months). Sixty-three (57%) were ongoing, 38 (34%) had discontinued felbamate and a further 10 (9%) were withdrawing. Reasons for discontinuing felbamate were adverse events in 23 (21%), increase in seizures in 11 (10%) and lack of efficacy in 14 (12%). Behavioural disturbances occurred in 14 patients, being the most likely adverse event to result in discontinuation. No cases of aplastic anaemia or liver failure were observed in this group. Felbamate appears to be a broad-spectrum AED. Seven percent of the patients had more than 95% seizure reduction (2 patients were seizure free), whilst a further 13% had significant improvement ( > 50% reduction in seizure frequency). In conclusion, felbamate seems to be an effective AED. In view of its association with potentially life-threatening complications, its use should however be restricted to patients with medically refractory epilepsy.
Authors:
L M Li; L Nashef; J Moriarty; J S Duncan; J W Sander
Related Documents :
3519174 - Drug treatment of epilepsy. outlines, criticism and perspectives.
9737444 - Acth therapy for infantile spasms: a combination therapy with high-dose pyridoxal phosp...
2398384 - Early postoperative seizures after posterior fossa surgery.
18808424 - Levetiracetam in absence epilepsy.
11772164 - New design of a palatal lift prosthesis combined with a palatal bar.
2019894 - The transmandibular implant: a 13-year survey of its use.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  European neurology     Volume:  36     ISSN:  0014-3022     ISO Abbreviation:  Eur. Neurol.     Publication Date:  1996  
Date Detail:
Created Date:  1996-11-14     Completed Date:  1996-11-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0150760     Medline TA:  Eur Neurol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  146-8     Citation Subset:  IM    
Affiliation:
Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anemia, Aplastic / chemically induced*
Anticonvulsants / adverse effects*
Epilepsy / complications,  drug therapy*
Follow-Up Studies
Humans
Liver Failure / chemically induced*
Phenylcarbamates
Propylene Glycols / adverse effects*
Chemical
Reg. No./Substance:
0/Anticonvulsants; 0/Phenylcarbamates; 0/Propylene Glycols; 25451-15-4/felbamate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Myoglobinuria due to quail poisoning.
Next Document:  Investigations on the point mutations at nt 5460 of the mtDNA in different neurodegenerative and neu...